This announcement is a separate document:
6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.